Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature

被引：20

作者：

Ali, Zeeshan ^{[1
]}

Zafar, Muhammad Usman ^{[2
]}

Wolfe, Zachary ^{[3
]}

Akbar, Faisal ^{[3
]}

Lash, Bradley ^{[3
]}

机构：

[1] Lehigh Valley Hlth Network, Hematol & Oncol, Allentown, PA 18103 USA

[2] Lehigh Valley Hlth Network, Hosp Med, Allentown, PA USA

[3] Lehigh Valley Hlth Network, Hematol & Med Oncol, Allentown, PA USA

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2020年 / 12卷 / 10期

关键词：

thrombotic thrombocytopenic thrombocytopenia; immune check-point inhibitors; immunotherapy-related adverse events; caplacizumab; IPILIMUMAB;

D O I：

10.7759/cureus.11246

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In recent years, the role of immune checkpoint inhibitors (ICI) in cancer treatment has rapidly expanded. In randomized clinical trials, these agents have demonstrated clinical efficacy in extending survival and increasing response rates. Immune-related adverse effects (irAEs) involving various organs have been frequently narrated. Herein, we present a case report of thrombotic thrombocytopenic purpura (TTP) as a rare side effect of nivolumab, plus ipilimumab, in the treatment of metastatic renal cell carcinoma (RCC). A review of the literature for other case reports of TTP during treatment with ICIs was also performed. Our aim is to elucidate the significance of early recognition of this rare adverse effect in patients being treated with this relatively newer class of medications.

引用

页数：3

共 10 条

[1]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]

[2] Pembrolizumab-induced thrombotic thrombocytopenic purpura [J].

Dickey, Marcus S. R. ;

Raina, Anant J. ;

Gilbar, Peter J. ;

Wisniowski, Brendan L. ;

Collins, Joel T. ;

Karki, Bhaskar ;

Nguyen, Andrew D. k .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (05) :1237-1240

[3] Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials [J].

Heng, D. Y. C. ;

Choueiri, T. K. ;

Rini, B. I. ;

Lee, J. ;

Yuasa, T. ;

Pal, S. K. ;

Srinivas, S. ;

Bjarnason, G. A. ;

Knox, J. J. ;

MacKenzie, M. ;

Vaishampayan, U. N. ;

Tan, M. H. ;

Rha, S. Y. ;

Donskov, F. ;

Agarwal, N. ;

Kollmannsberger, C. ;

North, S. ;

Wood, L. A. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :149-154

[4] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[5] Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP) [J].

King, Jeanelle ;

de la Cruz, Javier ;

Lutzky, Jose .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[6] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

[7] Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma [J].

Motzer, RJ ;

Mazumdar, M ;

Bacik, J ;

Berg, W ;

Amsterdam, A ;

Ferrara, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2530-2540

[8] Pathophysiology of thrombotic thrombocytopenic purpura [J].

Sadler, J. Evan .

BLOOD, 2017, 130 (10) :1181-1188

[9] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma [J].

Weber, J. ;

Mandala, M. ;

Del Vecchio, M. ;

Gogas, H. J. ;

Arance, A. M. ;

Cowey, C. L. ;

Dalle, S. ;

Schenker, M. ;

Chiarion-Sileni, V. ;

Marquez-Rodas, I. ;

Grob, J-J. ;

Butler, M. O. ;

Middleton, M. R. ;

Maio, M. ;

Atkinson, V. ;

Queirolo, P. ;

Gonzalez, R. ;

Kudchadkar, R. R. ;

Smylie, M. ;

Meyer, N. ;

Mortier, L. ;

Atkins, M. B. ;

Long, G. V. ;

Bhatia, S. ;

Lebbe, C. ;

Rutkowski, P. ;

Yokota, K. ;

Yamazaki, N. ;

Kim, T. M. ;

de Pril, V. ;

Sabater, J. ;

Qureshi, A. ;

Larkin, J. ;

Ascierto, P. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1824-1835

[10] Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors [J].

Youssef, Alexey ;

Kasso, Nawara ;

Torloni, Antonio Sergio ;

Stanek, Michael ;

Dragovich, Tomislav ;

Gimbel, Mark ;

Mahmoud, Fade .

CASE REPORTS IN HEMATOLOGY, 2018, 2018

← 1 →